Hi All,
Could not find any thread on Glenmark Life Sciences(GLS) and hence started the thread. While the recent listing was definitely muted but fundamentals tell a very different story. Company is primarily into API business with a small proportion of business dedicated to CDMO. It has got 80% of Top 20 pharma companies as its clientele and has got an envious product range. It boasts of ~120 high-value products across cardiovascular, CNS, diabetes, anti-infectives and other therapy areas. These are all non-commoditized products. Additional capacity building is ongoing and Dahej facility should come with this additional capacity by early 2023. They are also coming up with a new Greenfiled facility in Solapur that will increase the current production by 100% in 3-4 years. Last quarter results were very strong. Management commentary was bullish where they talked about China+1 being real and demand environment is pretty solid. Track record has been good, no severe or import alerts has been issued for the company.
If anyone is tracking the company or has got any inputs, please do share your thoughts.
Thanks
Naveen
4 posts - 3 participants